Impax Laboratories, Inc. (NASDAQ:IPXL) Broker Price Targets For The Coming Week

Ruben Hill
October 18, 2017

It may be a bit easier to make sense of future stock market prospects after seeing how many companies hit or miss their marks. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, in addition to the development and marketing of branded products.

Drilling down into some additional metrics, we note that Impax Laboratories, Inc. (NasdaqGS:IPXL) is 2.195261. This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. Walleye Trading Limited Liability Com holds 0% or 11,800 shares. It has outperformed by 12.81% the S&P500.

The stock decreased 4.09% or $0.85 during the last trading session, reaching $19.95. About 713,415 shares traded. Impax Laboratories Inc (NASDAQ:IPXL) has declined 49.01% since October 17, 2016 and is downtrending.

Analysts await Impax Laboratories Inc (NASDAQ:IPXL) to report earnings on November, 8. After having $0.18 EPS previously, Impax Laboratories Inc's analysts see 5.56% EPS growth.

Together, Impax and Amneal are expected to have $700 million to $750 million in 2018 pro forma adjusted earnings before interest, taxes, depreciation and amortization - including the expected cost savings within the first year of the close. Comerica Bank now owns 81,477 shares of the specialty pharmaceutical company's stock worth $1,124,000 after acquiring an additional 2,869 shares during the period.

The Price Index is a ratio that indicates the return of a share price over a past period. The Norway-based Sector Gamma As has invested 1.38% in the stock. Dimensional Fund Advsrs Lp reported 3.24 million shares stake. Deutsche Bank AG set a $21.00 price objective on Impax Laboratories and gave the stock a "buy" rating in a research report on Monday, July 17th. This is calculated by taking the current share price and dividing by the share price one month ago.

Impax Laboratories, Inc.(NASDAQ:IPXL)'s stock has performed at 50.57% year to date.

NASDAQ:IPXL) was up +0.24% ($0.05) to $20.8 and showed a volume of 0.79 mln shares. The company has an average rating of "Hold" and a consensus price target of $18.92. The company was upgraded on Tuesday, September 27 by Goldman Sachs. All told, the new company will have roughly 150 pending Abbreviated New Drug Applications.

Bisaro, was largely behind transforming a much smaller generic drugmaker Watson Pharmaceuticals, which was at about $2 billion in market cap, into the current version of Allergan with a market valuation of about $80 billion. The Firm focuses on the design, construction and sale of consumer-driven homes in various metropolitan areas within certain markets in California and Arizona, including coastal Southern California, the San Francisco Bay area, metro Sacramento and the greater Phoenix area. The Company operates in two segments, which include Impax Generics and Impax Specialty Pharma.

Impax 2017 guidance: non-GAAP EPS: $0.55 - 0.70. Its down 0.40, from 1.3 in 2017Q1. Glenmede Tru Company Na stated it has 196 shares or 0% of all its holdings. Moreover, Psagot Inv House Ltd has 0.02% invested in Procter & Gamble Co (NYSE:PG). 24,522 were accumulated by Private Harbour Inv Mgmt And Counsel Ltd Liability Com. Vanguard Grp Inc invested in 0.01% or 6.82M shares. Fishman Jay A Ltd Mi invested in 0% or 22,670 shares. Profund Advsr Limited Liability Corp reported 14,715 shares. Ftb Advsrs holds 0% or 420 shares in its portfolio. Alps Advisors reported 66,525 shares stake. Companies may issue new shares and buy back their own shares.

As of quarter end Gw&k Investment Management, LLC had disposed of 3,289 shares trimming its position 0.4%. State Street Corporation invested in 0% or 198,475 shares.

Other hedge funds and other institutional investors have also made changes to their positions in the company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER